☆ 4.4 Article

Therapy Switches in Fingolimod-Treated Patients with Multiple Sclerosis: Long-Term Experience from the German MS Registry

NEUROLOGY AND THERAPY (2022)

Related references

Note: Only part of the references are listed.

Article Clinical Neurology

What happens after fingolimod discontinuation? A multicentre real-life experience

Doriana Landi et al.

Summary: The study found that the main reason for discontinuation of fingolimod was inefficacy. One-third of patients experienced a relapse in the year after discontinuation, with 15% experiencing severe reactivation and approximately 50% having new/enhancing lesions on MRI. Risk factors for disease activity after discontinuation included low lymphocyte count and younger age.

JOURNAL OF NEUROLOGY (2022)

Add to Collection

Article Clinical Neurology

Effect of applying inclusion and exclusion criteria of phase III clinical trials to multiple sclerosis patients in routine clinical care

Kris Oliver Jalusic et al.

Summary: The majority of multiple sclerosis (MS) patients treated in routine care would not have met the eligibility criteria for phase III clinical trials, with relapse being the most common criterion not fulfilled. The study suggests that broader inclusion criteria in clinical trials could improve generalizability of the results.

MULTIPLE SCLEROSIS JOURNAL (2021)

Add to Collection

Review Immunology

Safety of Newer Disease Modifying Therapies in Multiple Sclerosis

Georges Jalkh et al.

Summary: In the past decade, the therapeutic options for multiple sclerosis have greatly expanded, with newer and more effective disease modifying therapies being increasingly used early in the disease course. Despite their advantages in controlling disease activity and improving long-term outcomes, these newer therapies come with safety concerns and monitoring requirements that highlight the need for periodic re-evaluation and adjustment of monitoring strategies for optimizing treatment safety in an individualized manner.

VACCINES (2021)

Add to Collection

Article Health Care Sciences & Services

Efficacy classification of modern therapies in multiple sclerosis

Imtiaz A. Samjoo et al.

Summary: According to the ABN guidelines, cladribine and ofatumumab are classified as high efficacy treatments, while ocrelizumab and ozanimod (1.0 mg) are classified as moderate or high efficacy depending on the approach used.

JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH (2021)

Add to Collection

Article Clinical Neurology

Descriptive Analysis of Real-World Data on Fingolimod Long-Term Treatment of Young Adult RRMS Patients

Tjalf Ziemssen et al.

Summary: The study found that young patients had lower disability scores compared to older patients at baseline but higher relapse rates, which significantly decreased in all age groups after 5 years of treatment. The proportion of patients with no clinical disease activity in year 4 varied among different age groups.

FRONTIERS IN NEUROLOGY (2021)

Add to Collection

Article Clinical Neurology

Age and sex as determinants of treatment decisions in patients with relapsing-remitting MS

Per Soelberg Sorensen et al.

Summary: Age and sex are independent determinants for the choice of the initial disease-modifying therapy and for the decision of treatment escalation in patients with breakthrough disease on a moderate efficacy therapy. Younger age and male patients are more likely to start with a high efficacy therapy initially, while older age and female patients are more likely to stick to the initial treatment and find it harder to accept treatment escalation.

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2021)

Add to Collection

Article Clinical Neurology

Interferon-β Is Less Effective Than Other Drugs in Controlling the Rate of Retinal Ganglion Cell Loss in MS

Yuyi You et al.

Summary: The study suggests that progressive loss of retinal ganglion cells in patients with MS is more pronounced in patients treated with interferon-beta compared to other disease-modifying therapies. This finding may have implications for decision-making regarding treatment selection for MS patients.

NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2021)

Add to Collection

Article Multidisciplinary Sciences

Chances and challenges of a long-term data repository in multiple sclerosis: 20th birthday of the German MS registry

Lisa-Marie Ohle et al.

Summary: The German MS Registry (GMSR) was established in 2001 to serve as a long-term data repository for MS healthcare research in Germany. As of 8 January 2021, 187 centres are participating in the registry, with over 196,000 visits recorded related to more than 33,000 persons with MS.

SCIENTIFIC REPORTS (2021)

Add to Collection

Article Health Care Sciences & Services

The Change of Fingolimod Patient Profiles over Time: A Descriptive Analysis of Two Non-Interventional Studies PANGAEA and PANGAEA 2.0

Tjalf Ziemssen et al.

Summary: The mean age of patients in PANGAEA and PANGAEA 2.0 was similar, but PANGAEA 2.0 patients had shorter disease duration and fewer relapses. Disease severity at baseline was lower in PANGAEA 2.0 patients compared to PANGAEA. These results suggest changes in treatment guidelines may have influenced patient profiles over time, with earlier intervention seen in patients initiating fingolimod therapy.

JOURNAL OF PERSONALIZED MEDICINE (2021)

Add to Collection

Review Pharmacology & Pharmacy

Polypharmacy among patients with multiple sclerosis: a qualitative systematic review

Niklas Frahm et al.

EXPERT OPINION ON DRUG SAFETY (2020)

Add to Collection

Review Clinical Neurology

Cryptococcus neoformans var grubii meningoencephalitis in a patient on fingolimod for relapsing-remitting multiple sclerosis: Case report and review of published cases

S. B. Ma et al.

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2020)

Add to Collection

Article Clinical Neurology

Rituximab, MS, and pregnancy

Jessica B. Smith et al.

NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2020)

Add to Collection

Article Clinical Neurology

Prevention of rebound effect after natalizumab withdrawal in multiple sclerosis. Study of two high-dose methylprednisolone schedules

Luna Fuentes-Rumi et al.

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2020)

Add to Collection

Article Clinical Neurology

Lymphocyte recovery after fingolimod discontinuation in patients with MS

Sara Nagy et al.

NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2020)

Add to Collection

Article Clinical Neurology

Symptomatology and symptomatic treatment in multiple sclerosis: Results from a nationwide MS registry

Paulus Stefan Rommer et al.

MULTIPLE SCLEROSIS JOURNAL (2019)

Add to Collection

Review Immunology

A review of the evidence for a natalizumab exit strategy for patients with multiple sclerosis

Johann Sellner et al.

AUTOIMMUNITY REVIEWS (2019)

Add to Collection

Review Clinical Neurology

Multiple sclerosis - a review

R. Dobson et al.

EUROPEAN JOURNAL OF NEUROLOGY (2019)

Add to Collection

Article Clinical Neurology

Comparative discontinuation, effectiveness, and switching practices of dimethyl fumarate and fingolimod at 36-month follow-up

Brandi Vollmer et al.

JOURNAL OF THE NEUROLOGICAL SCIENCES (2019)

Add to Collection

Review Clinical Neurology

Fingolimod Rebound: A Review of the Clinical Experience and Management Considerations

Brian Barry et al.

NEUROLOGY AND THERAPY (2019)

Add to Collection

Article Clinical Neurology

Real-world persistence and benefit-risk profile of fingolimod over 36 months in Germany

Tjalf Ziemssen et al.

NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2019)

Add to Collection

Article Clinical Neurology

Reasons to switch: a noninterventional study evaluating immunotherapy switches in a large German multicentre cohort of patients with relapsing-remitting multiple sclerosis

Mathias Maeurer et al.

THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2019)

Add to Collection

Review Clinical Neurology

Managing Multiple Sclerosis: Treatment Initiation, Modification, and Sequencing

Mark S. Freedman et al.

CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES (2018)

Add to Collection

Review Pharmacology & Pharmacy

Managing the side effects of multiple sclerosis therapy: pharmacotherapy options for patients

Paulus S. Rommer et al.

EXPERT OPINION ON PHARMACOTHERAPY (2018)

Add to Collection

Article Medicine, General & Internal

Disease Exacerbation after the Cessation of Fingolimod Treatment in Japanese Patients with Multiple Sclerosis

Kazunori Sato et al.

INTERNAL MEDICINE (2018)

Add to Collection

Review Medicine, General & Internal

Multiple sclerosis

Alan J. Thompson et al.

LANCET (2018)

Add to Collection

Review Pharmacology & Pharmacy

Fingolimod hydrochloride for the treatment of relapsing remitting multiple sclerosis

Katja Thomas et al.

EXPERT OPINION ON PHARMACOTHERAPY (2017)

Add to Collection

Article Clinical Neurology

Meta-analysis of the Age-Dependent Efficacy of Multiple Sclerosis Treatments

Ann Marie Weideman et al.

FRONTIERS IN NEUROLOGY (2017)

Add to Collection

Article Clinical Neurology

An observational study of alemtuzumab following fingolimod for multiple sclerosis

Mark Willis et al.

NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2017)

Add to Collection

Article Clinical Neurology

Rebound Syndrome in Patients With Multiple Sclerosis After Cessation of Fingolimod Treatment

Stacy Ellen Hatcher et al.

JAMA NEUROLOGY (2016)

Add to Collection

Article Immunology

Severe disease reactivation in four patients with relapsing-remitting multiple sclerosis after fingolimod cessation

Benjamin Berger et al.

JOURNAL OF NEUROIMMUNOLOGY (2015)

Add to Collection

Review Health Care Sciences & Services

Bridging, switching or drug holidays - how to treat a patient who stops natalizumab?

Joachim Havla et al.

THERAPEUTICS AND CLINICAL RISK MANAGEMENT (2013)

Add to Collection

Article Clinical Neurology

Relapse severity and recovery in early pediatric multiple sclerosis

Alex J. Fay et al.

MULTIPLE SCLEROSIS JOURNAL (2012)

Add to Collection

Review Clinical Neurology

Fingolimod compassionate use program. Case study on the concept of a therapy option for multiple sclerosis prior to marketing approval

J. Haas et al.

NERVENARZT (2012)

Add to Collection

Article Medicine, General & Internal

Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis

Jeffrey A. Cohen et al.

NEW ENGLAND JOURNAL OF MEDICINE (2010)

Add to Collection

Article

Increased Relapse Rate in Pediatric-Onset Compared With Adult-Onset Multiple Sclerosis

Mark P. Gorman et al.

ARCHIVES OF NEUROLOGY (2009)

Add to Collection

© Peeref 2019-2024. All rights reserved.